UPDATE: Goldman Sachs Starts TG Therapeutics (TGTX) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual Meeting
April 16, 2021 7:30 AM EDTUblituximab demonstrated superiority versus teriflunomide in reducing annualized relapse rates and MRI brain lesions
Ublituximab was generally well tolerated, with no unexpected safety signals
BLA submission targeted in Q3 2021
Webcast to be held today, Friday, April 16, 2021 at 8:30 AM ET
NEW YORK, April... More



